Real-world effectiveness and safety of sofosbuvir/velpatasvir and ledipasvir/sofosbuvir hepatitis C treatment in a single centre in Germany.

by Peter Buggisch, Karsten Wursthorn, Albrecht Stoehr, Petar K Atanasov, Romain Supiot, Janet Lee, Jie Ting, Joerg Petersen
Published 2019-01-01

Alcohol and Cannabis Consumption Does Not Diminish Cure Rates in a Real-World Cohort of Chronic Hepatitis C Virus Infected Patients on Opioid Substitution Therapy—Data From the Ger...

by Stefan Christensen, Peter Buggisch, Stefan Mauss, Klaus HW Böker, Tobias Müller, Hartwig Klinker, Tim Zimmermann, Yvonne Serfert, Bernd Weber, Jens Reimer, Heiner Wedemeyer
Published 2019-03-01

A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection

by Fabien Zoulim, Christophe Moreno, Samuel S. Lee, Peter Buggisch, Andrzej Horban, Eric Lawitz, Chris Corbett, Oliver Lenz, Bart Fevery, Thierry Verbinnen, Umesh Shukla, Wolfgang Jessner
Published 2018-01-01

Prediction of minimal residual viremia in HCV type 1 infected patients receiving interferon-based therapy

by Viola Knop, Gerlinde Teuber, Hartwig Klinker, Bernd Möller, Jens Rasenack, Holger Hinrichsen, Tilman Gerlach, Ulrich Spengler, Peter Buggisch, Konrad Neumann, Christoph Sarrazin, Stefan Zeuzem, Thomas Berg
Published 2013-03-01

Barriers to initiation of hepatitis C virus therapy in Germany: A retrospective, case-controlled study.

by Peter Buggisch, Hans Heiken, Stefan Mauss, Bernd Weber, Maria-Christina Jung, Herbert Görne, Renate Heyne, Holger Hinrichsen, Dennis Hidde, Bettina König, Ana Gabriela Pires Dos Santos, Claus Niederau, Thomas Berg
Published 2021-01-01

An Open-Label Trial of 12-Week Simeprevir plus Peginterferon/Ribavirin (PR) in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 1 (GT1).

by Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Robert Ryan, Oliver Lenz, Jane Scott, Gino Van Dooren, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti
Published 2016-01-01

Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate...

by Tarik Asselah, Christophe Moreno, Christoph Sarrazin, Michael Gschwantler, Graham R Foster, Antonio Craxí, Peter Buggisch, Faisal Sanai, Ceyhun Bicer, Oliver Lenz, Gino Van Dooren, Catherine Nalpas, Isabelle Lonjon-Domanec, Michael Schlag, Maria Buti
Published 2017-01-01

The Fatty Liver Assessment in Germany (FLAG) cohort study identifies large heterogeneity in NAFLD care

by Wolf Peter Hofmann, Peter Buggisch, Lisa Schubert, Nektarios Dikopoulos, Jeannette Schwenzer, Marion Muche, Gisela Felten, Renate Heyne, Patrick Ingiliz, Anna Schmidt, Kerstin Stein, Heiner Wedemeyer, Thomas Berg, Johannes Wiegand, Frank Lammert, Stefan Zeuzem, Jörn M. Schattenberg
Published 2020-12-01

Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients.

by Georgios Grammatikos, Christian Lange, Simone Susser, Susanne Schwendy, Nektarios Dikopoulos, Peter Buggisch, Jens Encke, Gerlinde Teuber, Tobias Goeser, Robert Thimme, Hartwig Klinker, Wulf O Boecher, Ewert Schulte-Frohlinde, Marissa Penna-Martinez, Klaus Badenhoop, Stefan Zeuzem, Thomas Berg, Christoph Sarrazin
Published 2014-01-01

Treatment of naïve patients with chronic hepatitis C genotypes 2 and 3 with pegylated interferon alpha and ribavirin in a real world setting: relevance for the new era of DAA.

by Benjamin Heidrich, Steffen B Wiegand, Peter Buggisch, Holger Hinrichsen, Ralph Link, Bernd Möller, Klaus H W Böker, Gerlinde Teuber, Hartwig Klinker, Elmar Zehnter, Uwe Naumann, Heiner W Busch, Benjamin Maasoumy, Undine Baum, Svenja Hardtke, Michael P Manns, Heiner Wedemeyer, Jörg Petersen, Markus Cornberg, HepNet Study Group
Published 2014-01-01